Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
Cui J, Philo L, Nguyen P, Hofflich H, Hernandez C, Bettencourt R, Richards L, Salotti J, Bhatt A, Hooker J, Haufe W, Hooker C, Brenner DA, Sirlin CB, Loomba R. Cui J, et al. J Hepatol. 2016 Aug;65(2):369-76. doi: 10.1016/j.jhep.2016.04.021. Epub 2016 May 2. J Hepatol. 2016. PMID: 27151177 Free PMC article. Clinical Trial.
BACKGROUND & AIMS: Uncontrolled studies show sitagliptin, an oral DPP-4 inhibitor, may improve alanine aminotransferase and liver histology in non-alcoholic fatty liver disease (NAFLD) patients. ...LAY SUMMARY: In a randomiz
BACKGROUND & AIMS: Uncontrolled studies show sitagliptin, an oral DPP-4 inhibitor, may improve alanine aminotransferase and li
Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial.
Joy TR, McKenzie CA, Tirona RG, Summers K, Seney S, Chakrabarti S, Malhotra N, Beaton MD. Joy TR, et al. World J Gastroenterol. 2017 Jan 7;23(1):141-150. doi: 10.3748/wjg.v23.i1.141. World J Gastroenterol. 2017. PMID: 28104990 Free PMC article. Clinical Trial.
AIM: To evaluate the effect of sitagliptin vs placebo on histologic and non-histologic parameters of non-alcoholic steatohepatitis (NASH). METHODS: Twelve patients with biopsy-proven NASH were randomized to sitagliptin (100 …
AIM: To evaluate the effect of sitagliptin vs placebo on histologic and non-histologic parameters of non- …